Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults

Posted: May 2, 2022 at 2:43 am

ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older. The FDA has now approved Qelbree for the treatment of ADHD in children (starting at age 6), adolescents and adults.

The rest is here:
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults

Related Posts